KR20180080142A - Therapeutic composition of bovine mastitis - Google Patents

Abstract

The present invention relates to a composition for preventing or treating mastitis of even-toed ungulates. More specifically, the present invention relates to a composition for preventing or treating mastitis of even-toed ungulates, which contains at least one among gentamicin, sulfase, trimethoprim, and egg white as an antimicrobial agent.

Description

Therapeutic composition of bovine mastitis < RTI ID = 0.0 >

The present invention relates to a composition for treating bovine mastitis, and more particularly, to a composition for preventing or treating mastitis which can effectively prevent or treat mastitis of a right-wing animal caused by various causative bacteria.

Staphylococcus aureus , E. coli , and S treptococcus agalactiae were the major causative organisms of bovine mastitis. Recently, however, the relative frequency of bacterial pathogens such as CNS and Gram negative bacteria other than E. coli has been increasing. In 2006-2010, subclinical mastitis was reported in 38.4% of CNS, 24.4% of Gram negative bacilli, 18.8% of S. aureus , 6.8% of streptococci, 4.8% of enterococci and 6.6% of microbacteriostats. Is known to be common. In the case of CNS, S. chromogenes was dominant in 38.1% in the case of Tennessee in the United States and S. hyicus was dominant in 37.2% in Louisiana in the case of USA. The frequency of domestic CNS was 39.0% for S. auricularis , 18.3% for S. simulans , 12.4% for S. haemolyticus , 8.2% for S. xylosus , 7.6% for S. sciuri , 7.1% for S. hominis , 4.1% for S. warneri , S. saprophyticus 1.7% and S. epidermidis was reported to be 0.9%.

Recently, resistance to bovine mastitis has been increasing, and it is necessary to select the best antibiotics because of the effect of combined infection and new causative agents. In addition, S. aureus and E. faecalis have already acquired tolerance, although lysozyme can be used because they are Gram positive bacteria. In recent years, susceptibility to lysozyme has been lacking in new mastitis pathogens, and lysozyme- The antimicrobial efficacy against bovine mastitis is unknown.

In the case of mastitis ointment currently on the market, there is no case where two antibiotics are mixed. In addition, there are various kinds of causative bacteria of mastitis, and even the same causative microorganisms are not susceptible to antibiotics, so that the optimum combination of antibiotics can not be easily obtained.

Therefore, the present inventors have found that when a bacterium causing bovine mastitis is isolated from crude oil samples, the combined infection of two or more kinds of bacteria is the most common, and when antibiotic susceptibility of isolated bacteria is examined, antibiotics ( S. hemolyticus, S. chromogenes ) and Lactococcus spp., Kocuria spp., Which have recently become candidates for mastitis. The inventors of the present invention completed the present invention as a therapeutic agent capable of replacing existing antibiotic products by completing the composition of the optimal mastitis therapeutic agent by confirming that the egg white has a higher antimicrobial activity than lysozyme.

The present invention relates to a mastitis composition (e.g., an ointment form) that can effectively treat bovine mastitis caused by various causative bacteria. More specifically, the present inventors have identified various causative microorganisms of bovine mastitis from crude oil, and have investigated susceptibility to antibiotics to develop combinations of antibiotics capable of inhibiting most causative microorganisms when used at different points of action. In addition, when the egg white is used more than the lysozyme purified from the egg white, it has been found that there is a high effect on the bacteria that are newly emerging as a cause of the mosaic virus and the mastitis causing the mastitis. The present invention can be used as a therapeutic agent for mastitis which can replace the conventional mastitis therapeutic agent and can prevent resistance.

The present invention provides a composition effective for preventing or treating mastitis in a right-hand animal, such as a bovine animal (such as a cow). An example of the present invention provides a composition for preventing or treating mastitis in a subject animal comprising one or more antimicrobial agents selected from the group consisting of gentamycin, sulfasulfate, trimethoprim, and egg white. In one embodiment, the composition may further comprise an anti-inflammatory agent. In one embodiment, the anti-inflammatory agent is used in an amount of 1 to 100 parts by weight, 1 to 80 parts by weight, 1 to 50 parts by weight, 10 to 100 parts by weight, 10 to 80 parts by weight, 10 to 50 parts by weight, 20 to 100 parts by weight, 20 to 80 parts by weight, or 20 to 50 parts by weight, but is not limited thereto. The anti-inflammatory agent may include one or more selected from the group consisting of dexamethasone and prednisolone. For example,

1) Gentamicin,

2) sulfasulfate and / or trimethoprim,

3) egg white,

4) Gentamycin and sulfa and / or trimethoprim,

5) Gentamicin and egg white,

6) Sulfases and / or trimethoprim and egg white, or

7) Gentamycin, sulfasulfate and / or trimethoprim, and egg white

, ≪ / RTI &

It may further include dexamethone and / or prednisolone in any one of the above-mentioned compositions 1) to 7).

The composition may be one that does not cause resistance.

Wherein the weight ratio of gentamycin and sulphate is from 1:10 to 10: 1, from 2: 8 to 8: 2, or from 3: 7 to 7: 3, the weight ratio of sulphate and trimethoprim is from 1:10 to 10: , From 2: 8 to 8: 2, or from 3: 7 to 7: 3.

The composition may contain 0.00001 to 99% by weight, preferably 0.001 to 80% by weight, based on the weight of solids of the whole composition, of one or more or at least two selected from the group consisting of gentamicin, sulfa, trimethoprim and egg white, 0.001 to 50% by weight.

Another example of the present invention may further include an emulsifier in the composition for preventing or treating mastitis of the above-mentioned animal. The emulsifier may be one comprising vegetable oil. In one example, the emulsifier is used in an amount of 1 to 100 parts by weight, 1 to 90 parts by weight, 1 to 50 parts by weight, 10 to 100 parts by weight, 10 to 80 parts by weight, 10 to 50 parts by weight, 30 to 100 parts by weight, 30 to 90 parts by weight, or 30 to 50 parts by weight, but is not limited thereto. In this case, the composition for preventing or treating mastitis in the subject animal may be formulated into an external preparation such as ointment.

Another embodiment of the present invention provides a method for preventing or treating mastitis in a subject animal comprising the step of administering the composition for preventing or treating mastitis to the subject.

Another example of the present invention provides an antimicrobial composition for a causative organism causing mastitis in an ovine animal comprising one or more antimicrobial agents selected from the group consisting of gentamycin, sulfase, trimethoprim, and egg white. In one embodiment, the antimicrobial composition may further comprise an anti-inflammatory agent. In one embodiment, the anti-inflammatory agent is used in an amount of 1 to 100 parts by weight, 1 to 80 parts by weight, 1 to 50 parts by weight, 10 to 100 parts by weight, 10 to 80 parts by weight, 10 to 50 parts by weight, 20 to 100 parts by weight, 20 to 80 parts by weight, or 20 to 50 parts by weight, but is not limited thereto. The anti-inflammatory agent may include one or more selected from the group consisting of dexamethasone and prednisolone. For example,

1) Gentamicin,

2) sulfasulfate and / or trimethoprim,

3) egg white,

4) Gentamycin and sulfa and / or trimethoprim,

5) Gentamicin and egg white,

6) Sulfases and / or trimethoprim and egg white, or

7) Gentamycin, sulfasulfate and / or trimethoprim, and egg white

, ≪ / RTI &

It may further include dexamethone and / or prednisolone in any one of the above-mentioned compositions 1) to 7).

The composition may be one that does not cause resistance.

Wherein the weight ratio of gentamycin and sulphate is from 1:10 to 10: 1, from 2: 8 to 8: 2, or from 3: 7 to 7: 3, the weight ratio of sulphate and trimethoprim is from 1:10 to 10: , From 2: 8 to 8: 2, or from 3: 7 to 7: 3.

The composition may contain 0.00001 to 99% by weight, preferably 0.001 to 80% by weight, based on the weight of solids of the whole composition, of one or more or at least two selected from the group consisting of gentamicin, sulfa, trimethoprim and egg white, 0.001 to 50% by weight.

Another example of the present invention may further include an emulsifier in the antimicrobial composition against the mastitis-causing microorganism of the above-mentioned animal. The emulsifier may be one comprising vegetable oil. In one example, the emulsifier is used in an amount of 1 to 100 parts by weight, 1 to 90 parts by weight, 1 to 50 parts by weight, 10 to 100 parts by weight, 10 to 80 parts by weight, 10 to 50 parts by weight, 30 to 100 parts by weight, 30 to 90 parts by weight, or 30 to 50 parts by weight, but is not limited thereto. In this case, the composition for preventing or treating mastitis in the subject animal may be formulated into an external preparation such as ointment.

The right-handed animal may be at least one selected from Bovidae animals including cattle, goats, sheep, nourishment, etc., and may be, for example, a cow.

The mastitis-inducing bacteria may be Staphylococcus spp. (E.g., S. aureus , S. chromogenes , S. hemolyticus, S. hyicus, S. simulans, S. epidermidis, S. warneri, S. vitulinus, S. auricularis, S. lugdunensis, etc.), Enterococcus spp. (E.g., E. faecalis, E. hirae, E. faecium, E. durans, E. avium, E. saccharolyticus, etc.), Streptococcus spp. (E. G., S. uberis, S. dysgalactiae ssp. , S. equisimilis, S. agalactolyticus, S. dysgalactiae ssp., S. dysgalactiae, S. infantarius ssp., S. coli , etc.), Kocuria spp. (E.g., K K. varians, K. kristinae, etc. ) , Lactococcus spp. (e.g., L. garvieae, L. lactis ssp. ), Aerococcus spp. (E.g., A. viridans ) , S. marcescens, A. hydrophila, K. oxytoca, H. alvei, Escherichia spp. (E.g., E. coli ) , and Raoutella spp. (For example, R. planticoli ), and the like. The antimicrobial composition may be one in which the causative bacteria are not resistant. In addition, the antimicrobial composition may not cause resistance.

In one example, the compositions provided herein may comprise,

1) containing gentamicin, Staphylococcus genus (e.g., S. chromogens, etc.), Kocuria genus (e. G., K. roesa etc.), Aerococcus genus (e. G., A. Viridans, etc.), E. coli, Serratia genus (e. G. , S. marcescens and the like), Raoultella genus (for example, R. planticola and the like), Hafnia genus (for example, H. alvei ), and / Or two or more of the mastitis of the subject animal;

2) Sulfases and / or trimethoprim, such as E. coli , genus Serratia (e.g., S. marcescens ), genus Raoultella (e.g., R. planticola ), Aeromonas genus (e.g., A. hydrophila / caviae ), The genus Hafnia (for example, H. alvei ), and / or the antimicrobial effect on one or more selected from the group consisting of / Or have a therapeutic effect;

3) In case of including egg white, it is preferable to use the strains of S. hemolyticus , Kocuria (such as K. roesa ), Staphylococcus (such as S. chromogens ), Lactococcus, Staphylococcus (such as S. aureus ) , Streptococcus S. uberis), Enterococcus (e.g., E. faecalis ) And / or may have a prophylactic and / or therapeutic effect on the mastitis of the above-mentioned one or more kinds of mastitis caused by the above-mentioned one or more;

4) genus Staphylococcus (such as S. chromogens ), genus of Kocuria (such as K. roesa ), Aerococcus (such as A. viridans ), or the like, including gentamycin and sulfatase and / or trimethoprim, Such as E. coli , the genus of Serratia (e.g., S. marcescens ), the genus Raoultella (e.g., R. planticola ), the genus Hafnia (e.g., H. alvei ), the genus Aeromonas (e.g., A. hydrophila / caviae ) And / or one or more of the above-mentioned one or more than one selected from the group consisting of mastitis;

5) gentamicin and those containing egg white, Staphylococcus genus (e.g., S. chromogens, such as S. aureus), Kocuria genus (e. G., K. roesa etc.), Aerococcus genus (e. G., A. Viridans, etc.), E. E. coli , Serratia (e.g., S. marcescens ), genus Raoultella (such as R. planticola ), genus Hafnia (such as H. alvei ), S. hemolyticus , Lactococcus, Streptococcus (such as S. uberis) Enterococcus sp. (E.g., E. faecalis ) And / or may have a prophylactic and / or therapeutic effect on the mastitis of the above-mentioned one or more kinds of mastitis caused by the above-mentioned one or more;

6) sulfonamides and / or a tree if they include meto Supreme and egg white, E. coli, Serratia genus (e.g., S. marcescens, etc.), Raoultella genus (e. G., R. planticola, etc.), Aeromonas genus (e. G., A. hydrophila / caviae), Hafnia genus (e.g., H. alvei),, S. hemolyticus , Kocuria genus (e. g., K. roesa etc.), Staphylococcus genus (e.g., S. chromogens, etc.), Lactococcus, Staphylococcus genus (e.g., S. aureus, etc.) , Streptococcus (e.g., S. uberis), Enterococcus (e.g., E. faecalis ) And / or may have a prophylactic and / or therapeutic effect on the mastitis of the above-mentioned one or more kinds of mastitis caused by the above-mentioned one or more;

7) genus Staphylococcus (e.g., S. chromogens, S. aureus, etc.), genus Kocuria (e.g., K. roesa etc.), genus Aerococcus , A. viridans, etc.), E. coli, Serratia genus (e.g., S. marcescens, etc.), Raoultella genus (e. g., R. planticola, etc.), Hafnia genus (e.g., H. alvei), Aeromonas genus (e. g., A. hydrophila / caviae , S. hemolyticus , Lactococcus, Streptococcus (e.g., S. uberis), Enterococcus (e.g., E. faecalis ) Etc., and / or a mastitis of the above-mentioned one or more kinds of mastitis caused by said at least one kind or two or more kinds of mastitis.

Another example of the present invention is a method for preventing mastitis in a subject animal, comprising the steps of (1) mixing one or more selected from the group consisting of gentamycin, sulfa and / or trimethoprim, and egg white, Or a composition for treatment, or a method for producing an antimicrobial composition for a causative organism causing mastitis in a subject animal. In one embodiment, the method comprises the steps of (2) mixing dexamethasone and / or prednisol, (3) mixing an emulsifier (such as one or more vegetable oils), or both can do. The steps (1), (2), and / or (3) may be performed simultaneously or sequentially.

In one embodiment, the method comprises: (1) mixing one or more selected from the group consisting of gentamycin, sulfa and / or trimetoprim, and egg white; And (2) mixing the mixture with dexamethasone and / or prednisolone, an anti-inflammatory agent.

In another embodiment, the method comprises the steps of: (1) mixing one or more selected from the group consisting of gentamicin, sulfa and / or trimethoprim, and egg white; And (3) mixing the mixture obtained in the step (1) with an emulsifier (for example, one or more kinds of vegetable oils) to prepare an ointment.

In another embodiment, the method comprises the steps of: (1) mixing one or more selected from the group consisting of gentamicin, sulfa and / or trimethoprim, and egg white; (2) mixing the mixture with dexamethasone and / or prednisolone, an anti-inflammatory agent; And (3) mixing an emulsifier (e.g., one or more kinds of vegetable oils, etc.) with the mixture obtained in the step (2) to prepare an ointment.

An egg white is a gel-like substance between egg yolk and egg shell in egg or reptile, which means viscous liquid around egg yolk.

The egg white used in the composition and the method may be an egg white of a bird such as a chicken, a duck, a goose, or the like, which has been sterilized or sterilized.

In the present specification, the term "sulfazine" refers to a sulfonamide derivative having a sulfonamide functional group, and includes sulfamethoxazole, sulfanilamide, sulfapyridine, sulfaporazole, sulfadiazine, sulfapassazole, homosulfamine, But is not limited thereto.

As used herein, the term " sulfa and / or trimethoprim " refers to a combination of sulfatase (such as sulfamethoxazole) and trimethoprim, for example, sulfamethoxazole and trimethoprim in a ratio of about 5: 1 (sulfamethoxazole weight: Trimethoprim weight), but these liver weight ratios are not limited thereto.

The composition of the present invention may be in the form of a pharmaceutical composition to be administered to a mammal, preferably a dairy herd, including a dairy cow, or to any of the commonly known forms of antimicrobial agents such as antimicrobial agents applied to air, skin, Applicable.

When the composition is used in the form of a pharmaceutical composition, it may further comprise suitable carriers, excipients and diluents conventionally used in the preparation of the pharmaceutical composition, and may be formulated into powders, granules, tablets, capsules, Oral formulations such as suspensions, emulsions, syrups and aerosols, external preparations, suppositories or sterilized injection solutions, and the like.

When the composition is formulated, it is prepared using a diluent such as a filler, an extender, a binder, a wetting agent, a disintegrant, a surfactant, or an excipient usually used. Solid formulations for oral administration include tablets, pills, powders, powders, granules, capsules and the like, and such solid preparations may contain at least one excipient and / or lubricant. Liquid preparations for oral administration include suspensions, solutions, emulsions, syrups and the like. Various excipients such as wetting agents, sweeteners, fragrances, preservatives and the like may be included in addition to water and liquid paraffin, which are simple diluents commonly used. have. Formulations for parenteral administration include injections, sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, suppositories, and the like.

The preferred dose of the composition can be appropriately determined depending on the symptom, body weight, drug form, route of administration and duration. The administration may be carried out once a day or divided into several doses. The composition of the present invention may be administered to animals, preferably mammals or birds, including cows, by a variety of routes. All modes of administration may be expected, for example, by transdermal, oral, intravenous, intramuscular, subcutaneous injection, and the like. In one example, the composition may be in the form of an ointment for transdermal administration. The pharmaceutical dosage form of the composition of the present invention may be used in the form of a pharmaceutically acceptable salt of the active ingredient, and may be used alone or in combination with other pharmaceutically active compounds as well as in a suitable combination.

The composition according to the present invention can be used for the prevention or treatment of mastitis in a subject animal or an antimicrobial composition for a causative microorganism causing mastitis in a subject animal.

Figure 1 is a photograph of a 96-well plate diluted with 2-fold dilution of duck and chicken egg white.

Hereinafter, the present invention will be described in more detail with reference to the following examples. However, these examples are only for illustrating the present invention, and the scope of the present invention is not limited by these examples.

Example 1: Identification of Bacterium causing Bovine Mastitis

Forty-two farm milk samples were diluted 10 ³ to 10 ⁵ times with sterile physiological saline and plated on 5% sheep blood agar medium (Han River, Korea) and cultured in a 37 ° C incubator. Cultured colonies were classified according to their size, shape and hemolytic type. The colonies were collected and cultured in Tryptic soy broth (TSB), followed by GP ID card for Gram-positive bacteria and GN ID card for Gram- And then mounted on a VITEK2 compact (bioMeriux, France) to identify the species. Table 1 shows the frequency of appearance of the above species.

Frequency of occurrence of bovine mastitis Genus Species Number of occurrences Occurrence frequency (%) Staphylococcus spp . 38 90.5 aureus 10 23.8 chromogenes 9 21.4 haemolyticus 6 14.3 hyicus 3 7.1 simulans 2 4.8 epidermidis 2 4.8 warnery 2 4.8 vitulinus 2 4.8 auricularis One 2.4 lugdunensis One 2.4 Enterococcus spp. 17 40.5 faecalis 12 28.6 hirae One 2.4 faecium One 2.4 durans One 2.4 avium One 2.4 saccharolyticus One 2.4 Streptococcus spp. 13 31.0 uberis 7 16.7 dysgalactiae ssp. equisimilis 2 4.8 agalactolyticus 2 4.8 dysgalactiae ssp. dysgalactiae One 2.4 infantarius ssp. coli One 2.4 Kocuria spp. 11 26.2 rosea 9 21.4 varians One 2.4 kristinae One 2.4 Lactococcus spp. 9 21.4 garveae 5 11.9 lactis ssp. lactis 4 9.5 Aerococcus viridans 5 11.9 Escherichia coli 3 7.1 Raoutella planticoli 3 7.1

Staphylococcus spp. Was detected in 90.5% of the samples, including S. aureus , S. chromogenes and S. hemolyticus in 23.8%, 21.4% and 21.4%, respectively . Respectively. Enterococcus spp. Was detected in 40.5% of the samples, of which E. faecalis accounted for 28.6%. Streptococcus spp. Was detected in 31.0% of the samples, of which S. uberis accounted for 16.7%. Recently, Kocuria spp. 26.2%, Lactococcus spp. Were detected in 21.4% of the cases, and frequently isolated as new causative agents.

Example 2: Investigation of antimicrobial resistance against bovine mastitis

(GM10), sulfamethoxazole / trimethoprim (SXT), streptomycin (S10), ampicillin (AM10), tetracycline (TE30), norfloxacin (NOR10), neomycin (N30) And clock factin (CX1).

Specifically, 390 crude milk samples were isolated from bovine mastitis, and the antimicrobial resistance of each causative organism was examined by disk diffusion method. The disk diffusion method was performed by a method described in CLSI using an antimicrobial disk (BD, USA). The tolerance of each causative organism to each antimicrobial agent is shown in Table 2.

Antibiotic resistance ratio by bacterium causing bovine mastitis Causative bacteria % of resistance to antibiotics * GM SXT S AM TE NOR N CX S. aureus 37.1 37.1 87.1 21.0 35.5 43.5 75.8 35.5 S. chromogens 0.0 28.0 16.0 16.0 16.0 4.0 8.0 52.0 E. faecalis 86.4 59.1 95.5 22.7 81.8 79.5 86.4 88.6 S. uberis 61.9 38.1 57.1 4.8 57.1 38.1 38.1 52.4 K. rosea 7.1 71.4 92.9 35.7 14.3 21.4 21.4 50.0 L. garvieae 43.3 83.3 80.0 23.3 76.7 76.7 73.3 93.3 A. viridans 0.0 9.1 18.2 0.0 9.1 18.2 0.0 36.4 E. coli 44.4 55.6 100 100 88.9 33.3 88.9 100 S. marcescens 5.3 15.8 89.5 94.7 94.7 5.3 15.8 100 R. planticola 42.9 57.1 85.7 100 100 28.6 85.7 100 A. hydrophila
/ caviae 36.4 9.1 72.7 100 63.6 0.0 18.2 100 K. oxytoca 83.3 83.3 83.3 100 83.3 66.7 83.3 100 H. alvei 0.0 0.0 0.0 100 66.7 0.0 33.3 100 Total (average) (34.5) (42.1) (67.5) (55.2) (60.6) (31.9) (48.3) (77.6)

N: neomycin, CX: cloxacillin), and the antimicrobial resistance (* All: resistance to all antibiotics, GM: gentamicin, SXT: sulphamethoxazole / trimethoprim, S: streptomycin, AM: ampicillin, TE: tetracycline, NOR: norfloxacin,

As a result, the average resistance of gentamycin alone was 34.5%, the resistance of sulfamethoxazole / trimethoprim was 42.1%, the resistance to other antibiotics was higher than that of streptomycin, Especially in the case of the test. Norfloxacin was similar in resistance to gentamycin or sulfamethoxazole / trimethoprim alone but was recently banned. On the other hand, when gentamycin and sulfamethoxazole / trimethoprim were mixed, the average antibiotic resistance of the causative bacteria listed in Table 2 was found to be 17%, and when gentamycin or sulfamethoxazole / trimethoprim alone was used, (83%) were more sensitive than antibiotics.

Example 3: Susceptibility to egg white and lysozyme by bacterium causing bovine mastitis

We investigated susceptibility of chicken and duck eggs to egg white and lysozyme by major causative bacteria of bovine mastitis.

Specifically, eggs of chickens and ducks were cleanly washed with 70% ethanol cotton, and aseptic egg white was separated and equilibrated with sterilized physiological saline to prepare chicken egg albumin and duck egg albumin samples. A lysozyme sample was prepared by dissolving lysozyme (Sigma-Aldrich Co., USA) at a concentration of 3 mg / ml in sterile physiological saline.

S. aureus, S. hemolyticus, S. chromogenes, S. uberis, Lactococcus, E. faecalis and Kocuria rosea were diluted to 100 cfu / 50ul in TSB and added to a 96-well plate.

The chicken egg white, Duck egg white and lysozyme samples were diluted from 32 to 8192 times by 2-fold dilution method and added to each well. After the incubation at 37 ° C in a thermostat, the highest dilution of the bacteria The results were as follows. Figure 1 is a photograph of a 96-well plate diluted with 2-fold dilution of duck and chicken egg white. The rightmost column in FIG. 1 is a control group to which no causative bacteria or antimicrobial substances are added to the medium, and the left column is a negative control group to which only causative bacteria are added without adding an antimicrobial substance to the medium. Table 3 shows the mean values of the highest dilution factor for each causative organism.

The highest dilution factor for each causative organism Chicken egg white Duck egg white Lysozyme S. hemolyticus 8192 8192 2048 K. rosea 4096 2048 2048 S. chromogenes 3072 2048 1024 Lactococcus lactis 768 768 512 S. uberis 192 126 0 E. faecalis 48 32 32

(* 0: when there is no effect even in undiluted undiluted solution)

As a result, for S. hemolyticus , chicken egg white, duck egg white and lysozyme showed antimicrobial activity to 8192 times, 8192 times, and 2048 times dilution, respectively. For K. rosea , chicken egg white, duck egg white and lysozyme showed antimicrobial activity up to 4096 times, 2048 times, and 2048 times dilution, respectively. For S. chromogenes , chicken egg white, duck egg white and lysozyme showed antimicrobial activity up to 3072 times, 2048 times, and 1024 times dilution, respectively. For Lactococcus , chicken egg white, duck egg white and lysozyme showed antimicrobial activity up to 768 times, 768 times, and 512 times dilution, respectively. For S. uberis , chicken eggs and duck eggs showed antimicrobial efficacy up to 192 times and 126 times dilutions, respectively, and lysozyme showed no antimicrobial activity in the undiluted solution.

For E. faecalis , chicken egg white, duck egg white and lysozyme showed antimicrobial activity up to 48, 32 and 32 times dilution, respectively. For major bacterium of bovine mastitis, egg white showed higher antibacterial activity than lysozyme, and egg white of chicken showed relatively high antibacterial effect.

Claims (12)

Wherein the composition comprises at least one antimicrobial agent selected from the group consisting of gentamycin, sulfa, trimethoprim and egg white. The method according to claim 1,
Wherein the composition comprises at least one anti-inflammatory agent selected from the group consisting of dexamethasone and prednisolone. Wherein the antimicrobial composition comprises at least one antimicrobial agent selected from the group consisting of gentamycin, sulfase, trimethoprim and egg white. The method of claim 3,
Wherein the composition comprises at least one anti-inflammatory agent selected from the group consisting of dexamethasone and prednisolone. 5. The method according to any one of claims 1 to 4,
Wherein the composition further comprises an emulsifier. 6. The method of claim 5,
Wherein the emulsifier is a vegetable oil. The method according to claim 6,
Wherein the composition is formulated in the form of an external preparation. 3. The method according to claim 1 or 2,
The mastitis Staphylococcus spp., Enterococcus spp., Streptococcus spp., Kocuria spp., Lactococcus spp., Aerococcus spp., S. marcescens, A. hydrophila, K. oxytoca, H. alvei, Escherichia spp., And Raoutella spp . ≪ RTI ID = 0.0 > 1, < / RTI > The method according to claim 3 or 4,
The above-mentioned mastitis-
Staphylococcus spp., Enterococcus spp., Streptococcus spp., Kocuria spp., Lactococcus spp., Aerococcus spp., S. marcescens, A. hydrophila, K. oxytoca, H. alvei, Escherichia spp., And Raoutella spp. Wherein the composition is at least one selected from the group consisting of: 5. The method according to any one of claims 1 to 4,
Wherein the egg white is egg yolk of a chicken or duck. 5. The method according to any one of claims 1 to 4,
Wherein said right head animal is one or more Bovidae animals selected from the group consisting of bovine, chlorine, sheep, and nutrition. The method according to claim 2 or 4,
Wherein the anti-inflammatory agent is contained in an amount of 1 to 100 parts by weight based on 100 parts by weight of the antibacterial agent.

Images